ImmuPharma PLC Investor Presentation 2020 | Lupuzor Pipeline

ImmuPharma PLC is a UK-listed biopharmaceutical company developing innovative peptide therapeutics across autoimmunity, metabolism, anti-infective, and oncology indications. The company's lead asset, Lupuzor (forigerimod), is in Phase III development for lupus with a targeted 2023 launch, supported by a US partnership secured in Q4 2019. ImmuPharma operates research facilities in Bordeaux, France in collaboration with the CNRS, and pursues a licensing strategy to advance its diversified pipeline.